
The Wall Street Journal @WSJ
FDA Commissioner Robert Califf defended the decision to approve the controversial Alzheimer’s drug Aduhelm after a congressional probe found “inappropriate” collaboration between the agency and Biogen https://t.co/ToAB4DYw5i — PolitiTweet.org